Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients

By Redekop W. Ken  

PharmacoEconomics, Vol. 26, Iss. 10, 2008-01 ,pp. : 861-877

Adis International

Access to resources Recommend Favorite

Insight into the Mode of Action of ACE Inhibition in Coronary Artery Disease: The Ultimate `EUROPA' Story

By Ferrari Roberto   Fox Kim  

Drugs, Vol. 69, Iss. 3, 2009-02 ,pp. : 265-277

Adis International

Access to resources Recommend Favorite

ACE Inhibition in Hypertension: Focus on Perindopril

By Cockcroft John R.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 5, 2007-01 ,pp. : 303-317

Adis International

Access to resources Recommend Favorite

ACE Inhibition with Moexipril: A Review of Potential Effects Beyond Blood Pressure Control

By Pines A.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 5, 2003-01 ,pp. : 351-360

Adis International

Access to resources Recommend Favorite